Improving drug delivery in paediatric medicine

Pharmaceutical Medicine

Volumn 22, Issue 1, 2008, Pages 41-50

  Krause, Julia ^a   Breitkreutz, Jörg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adolescents; Aerosols; Buccal; Children; Controlled release drugs; Drug delivery systems; Enema preparations; European Medicines Agency; Excipients; Granules; Infusion; Inhalation; Inhaler devices; Intravenous; Legislation; Microparticles; Neonates; Oral; Parenteral

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; CAFFEINE; ESTROGEN; FENTANYL; LAXATIVE; LEVODOPA; METHYLPHENIDATE; OLANZAPINE; PENICILLIN G; PHENYTOIN; PHLOROGLUCINOL; PSEUDOEPHEDRINE; SCOPOLAMINE; THEOPHYLLINE; TRIAMINIC; BENZALKONIUM CHLORIDE; BENZYL ALCOHOL; DYE; EXCIPIENT; PROPYLENE GLYCOL; SULFITE; THERAFLU; UNCLASSIFIED DRUG;

CHILD HEALTH CARE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG LEGISLATION; DRUG MARKETING; DRUG OVERDOSE; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; FREEZE DRYING; HALLUCINATION; HUMAN; INFUSION PUMP; NEBULIZER; NEWBORN PERIOD; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TABLET COMPRESSION; CHILD CARE; CLINICAL RESEARCH; DEVICE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG MANUFACTURE; DRUG PACKAGING; DRUG RELEASE; DRUG SURVEILLANCE PROGRAM; EXCIPIENT COMPATIBILITY; GENE DELIVERY SYSTEM; GENE TARGETING; HEALTH HAZARD; LAW; PRACTICE GUIDELINE;

EID: 40449102971     PISSN: 11782595     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256681     Document Type: Review

References (52)

1. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. New Engl J Med 2003; 349: 1157-67
2. Rakhmanina NY, van den Anker J. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 2006; 58: 4-14
3. Committee for Medicinal Products for Human Use (CHMP). Clinical investigations of medicinal products in the paediatric population. Note for guidance on clinical investigation of medicinal products in the paediatric population. EMEA/CHMP/ICH/2711/99 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ich/271199en.pdf [Accessed 2007 Dec 13]
4. Committee for Medicinal Products for Human Use (CHMP). Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG/ 194810/2005 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/paediatrics/ 19481005en.pdf [Accessed 2007 Dec 13]
5. Schirm E, Tobi H, Vries TW, et al. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 2003; 92: 1486-9
6. Breitkreutz J, Wessel T, Boos J. Dosage forms for peroral drug administration to children. Paediatr Perinat Drug Ther 1999; 3: 25-33
7. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv 2007; 4 (1): 37-45
8. MacDonald MG, Getson PR, Glasgow AM, et al. Propylene glycol: increased incidence of seizures in low birth weight infants. Pediatrics 1987; 79 (4): 622-5
9. Glover ML, Reed MD. Propylene glycol: the safe diluent that continues to cause harm. Pharmacotherapy 1996; 16 (4): 690-3
10. McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, doubleblinded, placebo-controlled trial. Lancet 2007; 370 (9598): 1560-7
11. Center for Drug Evaluation and Research (CDER), US Food and Drug Administration. Guidance for industry: testing of glycerine for diethylene glycol [online]. Available from URL: http://www.fda.gov/cder/guidance/7654fnl. htm [Accessed 2007 Dec 13]
12. O'Brien K, Selanikio J, Hecdivert C, et al. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA 1998; 279: 1175-80
13. Zeine C. Impurities in drug products [in German]. Pharm Ind 2007; 69 (5): 624-8
14. Breitkreutz J. Child-appropriate drug preparations for peroral administration [in German; habilitation thesis]. Münster: University of Münster, 2004
15. Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. European Commission [online]. Available from URL: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol- 1/reg_2006_ 1901/reg_2006_1901_en.pdf [Accessed 2008 Jan 3]
16. Standing JF, Khaki ZF, Wong ICK. Poor formulation information in published pediatric drug trials. Pediatrics 2005 Oct; 116 (4): 559-62
17. Matsui D. Assessing the palatability of medications in children. Paediatr Perinat Drug Ther 2007; 8 (2): 55-60
18. Zheng JY, Keeney MP. Taste masking analysis in pharmaceutical formulation development using an electronic tongue. Int J Pharm 2006 Jan; 310: 118-24
19. Grieaßmann K, Breitkreutz J, Schubert-Zsilavecz M, et al. Dosing accuracy of measuring devices provided with antibiotic oral suspensions. Paediatr Perinat Drug Ther 2007; 8 (2): 61-70
20. Lennartz P, Mielck JB. Minitabletting: improving the compactability of paracetamol powder mixtures. Int J Pharm 1998 Jun; 173: 75-85
21. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50: 375-82
22. Mishra R, Amin A. Quick API delivery. Pharm Technol Eur 2007; 10: 35-9
23. Aurora J, Pathak V. Oral disintegrating dosage forms: an overview. Drug Deliv Technol 2005; 5: 50-4
24. Cassidy JP, Landzert NM, Quadros E. Controlled buccal delivery of buprenorphine. J Control Rel 1993; 25: 21-9
25. Bénès L, Claustrat B, Horrière F et al. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. J Pharm Sci 1997; 86: 1115-9
26. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Rev 1997; 25: 47-58
27. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm 2000 Mar; 50: 161-77
28. Björk M, Wettergren B. Scopolamine patches cause hallucinations [in Swedish]. Läkartidningen 1995; 92: 638
29. Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperacitivity disorder in children. Drugs 2006; 66 (8): 1117-26
30. Berger WE. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Del 2005; 2 (6): 965-80
31. Schüepp K, Jauernig J, Janssens H, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med 2005; 18 (2): 225-35
32. Janssens H, De Jongste J, Hop W, et al. Extra-fine particles improve lung delivery of inhaled steroids in infants. Chest 2003; 123: 2083-8
33. Dolovich M. Influence of inspiratory flow rate, particle size and airway caliber in aerosolized drug delivery to the lung. Respir Care 2000; 45: 597-608
34. Geller D, Eigen H, Fiel S, et al. Effect of smaller droplet size of Dornase Alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 1998; 25: 83-7
35. Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 1996; 21: 276-81
36. Schüepp K, Straub D, Möller A, et al. Deposition of aerosols in infants and children. J Aerosol Med 2004; 17 (2): 153-6
37. Everard M. Inhaler devices in infants and children: challenges and solutions. J Aerosol Med 2004; 17 (2): 186-95
38. Devadason S, Everard M, Macerlean C, et al. Lung deposition from the Turbohaler in children with cystic fibrosis. Eur Respir J 1997; 10: 2023-8
39. Wildhaber J, Dore N, Wilson J, et al. Inhalation therapy in asthma: nebulizer or pressured metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28-33
40. Diot P, Palmer A, Smaldone A, et al. RhD-Nase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1662-8
41. Biggart E, Bush A. Antiasthmatic drug delivery in children. Pediatr Drugs 2002; 4 (2): 85-93
42. Collis G, Cole C, Le Souef P. Dilution of nebulized aerosols by air entrainment in children. Lancet 1990; 336: 341-3
43. Crompton G. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis 1982; 63: 101-42
44. Kamps A, Van Ewijk B, Roorda R, et al. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000; 29: 39-42
45. Everard M. Designing inhalers for children in the 21st century. In: Drug delivery 2007. London: Touch Briefings, 2007 Jun: 9-12
46. Tuleu C. Paediatric formulations in practice. In: Costello I, Long P, Wong I, et al., editors. Paediatric drug handling. London: Pharmaceutical Press, 2007: 70-2
47. Breitkreutz J, Tuleu C, Solomonidou D. Paediatric formulations. In: Rose K, van den Anker J, editors. Guide to paediatric clinical research. Basel: S. Karger, 2007
48. Wirtz V, Taxis K, Barber N. An observational study of intravenous medication errors in the United Kingdom and in Germany. Pharm World Sci 2003; 25: 104-11
49. Taxis K, Barber N. Incidence and severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol 2004; 59: 815-7
50. Allegaert K, Anderson BJ, Vrancken M. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates. Paediatr Perinat Drug Ther 2006; 7 (2): 59-63
51. Wurdack W, Kittlaus A, Pecar R, et al. Release of components from primary package materials and their migration into drug and nutrition solutions [in German]. Krankenhauspharmazie 2006; 27: 334-9
52. Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr Respir Rev 2007; 8: 62-6